Our mission is to detect cancer early, when it can be cured. We are working to change the trajectory of cancer mortality and bring stakeholders together to adopt innovative, safe, and effective technologies that can transform cancer care.

We are a healthcare company, pioneering new technologies to advance early cancer detection. We have built a multi-disciplinary organization of scientists, engineers, and physicians and we are using the power of next-generation sequencing (NGS), population-scale clinical studies, and state-of-the-art computer science and data science to overcome one of medicine’s greatest challenges.

GRAIL is headquartered in the bay area of California, with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies.

For more information, please visit grail.com

GRAIL is seeking a Data Analyst to be based in London (UK) to make a pivotal contribution to the analysis of the NHS-Galleri trial. NHS-Galleri is the first randomised controlled trial investigating the efficacy of a multi-cancer early detection (MCED) test in the NHS, with primary endpoints reporting in 2026. You will join the UK team at a very exciting time as we prepare for delivery of clinical studies that have the potential to transform the cancer screening landscape. You will use your exceptional knowledge of NHS cancer and health data sources to demonstrate the clinical utility and value proposition of GRAIL’s Galleri MCED test and support successful UK implementation.

You will normally be working a hybrid of remote and office based, with no less than 3 days in the office; when you are working out of our London office, you will be based at 210 Euston Road, London, NW1 2DA, in line with company needs.